Literature DB >> 34740478

Exercise capacity in the stair-climbing test predicts outcomes of operable esophageal cancer in minimally invasive era.

Anna Junttila1, Olli Helminen2, Johanna Mrena3, Eero Sihvo3.   

Abstract

INTRODUCTION: The risk of complications after esophagectomy highlights the need for careful preoperative assessment. Aim was to assess whether stair-climbing test (SCT) could predict outcomes of patients with operable esophageal cancer in minimally invasive era.
MATERIALS AND METHODS: Patients with esophageal cancer were evaluated for surgical treatment in Central Finland Central Hospital from 2012 to March 2021. Of evaluated 162 patients, 138 were scheduled to eventually undergo surgery. The exercise capacity was evaluated with symptom limited SCT. Patients were divided into four study groups on intent-to-treat basis: surgery and the SCT >14 m (Group 1), surgery and the SCT <11 m (Group 2), non-surgical therapy and the SCT <11 m (Group 3) and non-surgical therapy and the SCT >14 m (Group 4). Results were adjusted for confounders.
RESULTS: Major complication rate was 10.1% vs 40.0% between Group 1 and 2 (p = 0.006), and 90-day mortality 0% vs 20.0% (p < 0.001). Overall survival rates in Groups 1-4 at 1-year were 92.3% vs 72.2% vs 46.8% vs 81.8%, at 3-year 68.5% vs 52.7% vs 15.6% vs 27.3% and at 5-year 58.7% vs 39.5% vs 0% vs 0%, respectively (p < 0.001). In adjusted analysis when compared to Group 1, other groups had increased 5-year mortality hazard (Group 2 HR 2.88 (95% CI 1.25-6.63), Group 3 HR 15.6 (95% CI 5.57-43.5) and Group 4 HR 5.35 (95% CI 2.08-13.7)).
CONCLUSION: Exercise capacity measured with SCT in esophageal cancer patients is a strong predictor of complications and survival, and is a potential parameter to be included in any risk or prognostic models.
Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Esophageal cancer; Esophagectomy; Stair-climbing test

Mesh:

Year:  2021        PMID: 34740478     DOI: 10.1016/j.ejso.2021.10.024

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  2 in total

1.  Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors.

Authors:  Niko Hiltunen; Jukka Rintala; Juha P Väyrynen; Jan Böhm; Tuomo J Karttunen; Heikki Huhta; Olli Helminen
Journal:  Cancers (Basel)       Date:  2022-05-22       Impact factor: 6.575

2.  Implementation of Multimodality Therapy and Minimally Invasive Surgery: Short- and Long-term Outcomes of Gastric Cancer Surgery in Medium-Volume Center.

Authors:  Anna Junttila; Olli Helminen; Valtteri Kairaluoma; Anne Mattila; Eero Sihvo; Johanna Mrena
Journal:  J Gastrointest Surg       Date:  2022-08-24       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.